Anti-RAGE (Receptor Advanced Glycation End products) Antibody Improves Diabetic Retinopathy in Rats via Hypoglycemic and Anti-inflammatory Mechanism

  • سال انتشار: 1401
  • محل انتشار: مجله گزارش های بیوشیمی و زیست شناسی مولکولی، دوره: 11، شماره: 3
  • کد COI اختصاصی: JR_RBMB-11-3_004
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 129
دانلود فایل این مقاله

نویسندگان

Ramzi Amin

Department of Ophthalmology, Faculty of Medicine Universitas Sriwijaya/ Dr Moh Hoesin General Hospital, Palembang, Indonesia

Tiara Bunga Indiarsih

Specialized Residency Training, Faculty of Medicine Universitas Sriwijaya/Dr Moh Hoesin General Hospital, Palembang, Indonesia.

Prima Maya Sari

Department of Ophthalmology, Faculty of Medicine Universitas Sriwijaya/ Dr Moh Hoesin General Hospital, Palembang, Indonesia.

Petty Purwanita

Department of Ophthalmology, Faculty of Medicine Universitas Sriwijaya/ Dr Moh Hoesin General Hospital, Palembang, Indonesia.

چکیده

Background: Receptor advanced glycation end products (RAGE) activation plays an essential role in diabetic retinopathy (DR) progression. This study was aimed to explore the role of anti-RAGE antibodies (RAGE antagonists) in inhibiting DR progression through their hypoglycemic and anti inflammatory mechanism in diabetic retinopathy induced rats.   Methods: A total of ۳۰ male Wistar rats were randomly divided into five group. The group was consisted of normal control group, DR group without treatment, DR group with anti-RAGE ۱ g/kg BW, ۱۰ g/kg BW, and ۱۰۰ g/kg BW. To assess the diabetic retinopathy, fundus photographs were taken every week using a camera with ۱۶x magnification placed in front of the rat's eyes. Blood glucose was checked by the glucose oxidase-peroxidase method. Retinal TNF- levels and VEGF were examined using an enzyme-linked immunosorbent assay (ELISA) kit.   Results: The finding of this study showed that anti-RAGE treatment at dose of ۱۰ and ۱۰۰ g/kg BW, HbA۱c levels were significantly higher (p< ۰.۰۵) compared to the normal control group but significantly lower (p< ۰.۰۵) than in the diabetes group. The mean blood vessel diameter in the DR+anti-RAGE ۱۰ and ۱۰۰ g/kg BW groups was significantly lower than in the diabetic retinopathy group (p< ۰.۰۵). The administration of anti-RAGE ۱۰ and ۱۰۰ g/kg BW showed the ability to significantly reduce VEGF levels compared to the DR group (p< ۰.۰۵).   Conclusions:This study revealed at doses of ۱۰ and ۱۰۰ g/kg BW, anti-RAGE antibodies improved diabetic retinopathy in Wistar rats through hypoglycemic effects and anti-inflammatory mechanisms.

کلیدواژه ها

Anti-RAGE (Receptor Advanced Glycation End products), Diabetic Retinopathy, Glycated Hemoglobin A, Hypoglycemic Agents, Peroxidases, Vascular Endothelial Growth Factor A

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.